Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Darzalex Phase 3 Study Shows Efficacy and Safety Data of Anti-CD38 Monoclonal Antibody in Patients with Newly Diagnosed Multiple Myeloma

americanpharmaceuticalreviewDecember 06, 2018

Tag: Darzalex Phase 3 , Anti-CD38 , monoclonal antibody , Diagnosed Multiple Myeloma

PharmaSources Customer Service